Youcare Pharmaceutical's Subsidiary Receives FDA Clinical Trial Approval

Deep News11-30

On November 28, Youcare Pharmaceutical Group Co., Ltd. (referred to as "Youcare Pharmaceutical") announced that its wholly-owned subsidiary, Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. (referred to as "Youcare Kechuang"), has received approval from the U.S. Food and Drug Administration (FDA) for clinical trials of its YKYY018 aerosol inhalation solution. The FDA issued a Study May Proceed Letter (IND No.: 178457), allowing the drug to proceed with clinical trials for the prevention and treatment of respiratory syncytial virus (RSV) infection.

RSV is a widespread and contagious enveloped RNA virus that causes respiratory diseases, particularly affecting vulnerable groups such as children, the elderly, and immunocompromised individuals. Currently, there are no globally approved treatments for RSV infection, highlighting a significant and urgent unmet medical need in clinical practice.

YKYY018 aerosol inhalation solution is an internationally innovative membrane fusion inhibitor drug independently developed by Youcare Kechuang using a full-process AI platform, specifically targeting the prevention and treatment of RSV infection.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1107586420?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-30 22:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1107586420","market":"hk","top_or_hot":-1,"title":"Youcare Pharmaceutical's Subsidiary Receives FDA Clinical Trial Approval","media":"Deep News","content":"<p>On November 28, Youcare Pharmaceutical Group Co., Ltd. (referred to as \"Youcare Pharmaceutical\") announced that its wholly-owned subsidiary, Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. (referred to as \"Youcare Kechuang\"), has received approval from the U.S. Food and Drug Administration (FDA) for clinical trials of its YKYY018 aerosol inhalation solution. The FDA issued a Study May Proceed Letter (IND No.: 178457), allowing the drug to proceed with clinical trials for the prevention and treatment of respiratory syncytial virus (RSV) infection.</p>\n<p>RSV is a widespread and contagious enveloped RNA virus that causes respiratory diseases, particularly affecting vulnerable groups such as children, the elderly, and immunocompromised individuals. Currently, there are no globally approved treatments for RSV infection, highlighting a significant and urgent unmet medical need in clinical practice.</p>\n<p>YKYY018 aerosol inhalation solution is an internationally innovative membrane fusion inhibitor drug independently developed by Youcare Kechuang using a full-process AI platform, specifically targeting the prevention and treatment of RSV infection.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Youcare Pharmaceutical's Subsidiary Receives FDA Clinical Trial Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYoucare Pharmaceutical's Subsidiary Receives FDA Clinical Trial Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2025-11-30 22:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On November 28, Youcare Pharmaceutical Group Co., Ltd. (referred to as \"Youcare Pharmaceutical\") announced that its wholly-owned subsidiary, Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. (referred to as \"Youcare Kechuang\"), has received approval from the U.S. Food and Drug Administration (FDA) for clinical trials of its YKYY018 aerosol inhalation solution. The FDA issued a Study May Proceed Letter (IND No.: 178457), allowing the drug to proceed with clinical trials for the prevention and treatment of respiratory syncytial virus (RSV) infection.</p>\n<p>RSV is a widespread and contagious enveloped RNA virus that causes respiratory diseases, particularly affecting vulnerable groups such as children, the elderly, and immunocompromised individuals. Currently, there are no globally approved treatments for RSV infection, highlighting a significant and urgent unmet medical need in clinical practice.</p>\n<p>YKYY018 aerosol inhalation solution is an internationally innovative membrane fusion inhibitor drug independently developed by Youcare Kechuang using a full-process AI platform, specifically targeting the prevention and treatment of RSV infection.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1107586420","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1107586420","pubTimestamp":1764514263,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"On November 28, Youcare Pharmaceutical Group Co., Ltd. (referred to as \"Youcare Pharmaceutical\") announced that its wholly-owned subsidiary, Beijing Youcare Kechuang Pharmaceutical Technology Co.,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688658":"悦康药业","BK0239":"医药制造"},"translate_title":"优康药业子公司获FDA临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688658":1},"content_text":"On November 28, Youcare Pharmaceutical Group Co., Ltd. (referred to as \"Youcare Pharmaceutical\") announced that its wholly-owned subsidiary, Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. (referred to as \"Youcare Kechuang\"), has received approval from the U.S. Food and Drug Administration (FDA) for clinical trials of its YKYY018 aerosol inhalation solution. The FDA issued a Study May Proceed Letter (IND No.: 178457), allowing the drug to proceed with clinical trials for the prevention and treatment of respiratory syncytial virus (RSV) infection.\nRSV is a widespread and contagious enveloped RNA virus that causes respiratory diseases, particularly affecting vulnerable groups such as children, the elderly, and immunocompromised individuals. Currently, there are no globally approved treatments for RSV infection, highlighting a significant and urgent unmet medical need in clinical practice.\nYKYY018 aerosol inhalation solution is an internationally innovative membrane fusion inhibitor drug independently developed by Youcare Kechuang using a full-process AI platform, specifically targeting the prevention and treatment of RSV infection.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1107586420","isCrawlerRequest":true}